Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Crespo G, Jiménez-Fonseca P, Custodio A, López C, Carmona-Bayonas A, Alonso V, Navarro M, Aller J, Sevilla I, Grande E, Gajate P, Alonso-Gordoa T, Matos I, Capdevila J, Nieto B, Barriuso J.
Crespo G, et al. Among authors: grande e.
Future Oncol. 2017 Mar;13(7):615-624. doi: 10.2217/fon-2016-0434. Epub 2016 Nov 2.
Future Oncol. 2017.
PMID: 27802780